Biolargo Stock Price, News & Analysis

BioLargo (OTCQX:BLGO) announced its participation in WEFTEC 2025, North America's largest water quality event, where it will showcase its innovative PFAS remediation and odor control solutions at Booth #6009 from September 29 to October 1 in Chicago.

The company will feature its Aqueous Electrostatic Concentration (AEC) Solution, designed to efficiently remove and destroy various PFAS compounds, and CupriDyne® Clean, their patented odor and VOC control technology. Additionally, Verralize will demonstrate its PFAS Field Test Kits at BioLargo's booth, offering rapid on-site PFAS contamination detection capabilities.

BioLargo (OTCQX:BLGO) has revoked Pooph Inc.'s technology license and terminated their agreement due to Pooph's failure to meet contractual obligations, including approximately $3.8 million in unpaid fees. The termination requires Pooph to immediately cease marketing and selling products incorporating BioLargo's patents and proprietary technology.

Prior to termination, Pooph had successfully leveraged BioLargo's technology to achieve over $50 million in annual sales and garnered thousands of positive customer reviews. BioLargo remains focused on advancing its technology portfolio in infection control, wound care, "forever chemicals" management, and innovative battery systems while protecting its intellectual property rights.

BioLargo (OTCQX:BLGO), a cleantech and environmental solutions company, reported its Q2 2025 financial results with revenues of $2.77 million for Q2 and $6.04 million for H1 2025. The company highlighted significant progress across multiple divisions, with its engineering segment experiencing a 517% revenue increase in air quality control services.

Notable achievements include Clyra Medical Technologies securing distribution agreements covering 6,100 hospitals and thousands of medical facilities, while the company's Cellinity battery technology received validation from U.S. BESS Corporation and secured four MOUs for potential factory partnerships. As of June 30, 2025, BioLargo maintained a strong financial position with $3.47 million in cash, total assets of $12.49 million, and stockholders' equity of $6.06 million.

BioLargo (OTCQX:BLGO), a sustainable technology developer and environmental engineering company, will host a Q2 2025 earnings webcast and conference call on Friday, August 15th, 2025, at 11:00 AM ET.

The event will review financial results for the quarter ending June 30th, 2025, discuss recent milestones, and include a Q&A session. Participants can join via webcast or teleconference, with replay available until August 29th, 2026. Registration should be completed 15 minutes before the scheduled start time.

BioLargo (OTCQX:BLGO) provided a comprehensive mid-year review for 2025, highlighting significant progress across its subsidiaries. The company's 52%-owned Clyra Medical secured distribution agreements covering 6,100 hospitals and received a $3.3 million capital infusion. Their revolutionary Cellinity battery technology has attracted four MOUs for potential joint ventures, with each planned factory capable of generating $500 million in annual revenue. The company's PFAS water treatment technology is advancing with its first paid project in New Jersey and successful pilot programs for Fortune 500 clients. However, BioLargo faced challenges in its ONM Environmental division, experiencing decreased revenue and increased accounts receivable due to declining sales of private-labeled pet-odor control products.

BioLargo (OTCQX:BLGO) has initiated alpha testing of Verralize's portable PFAS water test kit at its Oak Ridge, Tennessee laboratory. The innovative "lab-on-a-sensor" kit enables rapid, on-site detection of PFAS (per- and polyfluoroalkyl substances), commonly known as "forever chemicals" regulated under the U.S. Safe Drinking Water Act.

The test kit's key features include user-friendly operation, low cost, and the ability to distinguish between different PFAS molecules. Testing will be conducted using contaminated water from BioLargo's existing and scheduled pilot projects. Upon successful validation, BioLargo plans to integrate the kit into its PFAS treatment services and distribute it through its nationwide network of manufacturer's sales representatives.

The company will showcase its PFAS solutions and the Verralize test kits at WEFTEC 2025 this September. This strategic initiative aims to enhance BioLargo's PFAS treatment systems and provide clients with real-time contamination monitoring capabilities.

BioLargo (OTCQX:BLGO), an environmental and cleantech solutions company, announced the approval of all matters at its 2025 annual stockholder meeting. While shareholders approved a potential 10-for-1 reverse stock split, management clarified they have no immediate plans to implement it.

CEO Dennis Calvert emphasized that the company would only consider the reverse split if needed to meet minimum price requirements for uplisting to Nasdaq or NYSE. BioLargo currently meets all uplisting qualifications except for stock price, and management views this approval as strategic preparation for potential future opportunities.

BioLargo (OTCQX:BLGO) has received independent validation from U.S. BESS Corporation confirming breakthrough performance of its Cellinity battery technology for grid-scale energy storage. The evaluation verified impressive specifications including >4.2V open circuit voltage, 120-250°C operating range, >500 Wh/kg energy density, and ~100% charge/discharge efficiency. Key advantages include no thermal runaway risks, domestically sourceable materials, absence of rare earth elements, and full recyclability. The technology addresses critical limitations of current lithium-ion batteries amid rapidly growing demand for grid storage, with U.S. battery storage capacity increasing 66% in 2024. BioLargo is now working on scaling up cell design and manufacturing, while pursuing manufacturing joint ventures for commercialization.

BioLargo (OTCQX:BLGO), a company focused on sustainable environmental and health technologies, has scheduled its Q1 2025 earnings conference call and webcast for Thursday, May 15, 2025, at 4:30 PM Eastern Time. The event will cover financial results for the quarter ending March 31, 2025, recent company milestones, and include a Q&A session.

Participants can join via webcast or teleconference, with domestic and international dial-in numbers provided. The webcast replay will be available until August 15, 2025, while the teleconference replay will be accessible until May 29, 2025. All presentation materials will be posted on BioLargo's investor relations website.